Combining established therapies with newer classes of drugs may be the best way to combat the high morbidity and mortality rates that are still associated with congestive heart failure. At present, no single drug can adequately improve quality of life and prevent disease progression, said researchers at Heart Failure '95 [Amsterdam, The Netherlands; April, 1995]. At the meeting, which was the first international conference to be devoted to heart failure research, a preliminary set of European guidelines for diagnosing and treating heart failure was presented.